Platyhelminthes
Tell them General Tso is coming
the latest weapon in Ukraine's fight
presenting…
Have a good day people
He's lost his protection…
it is a matter of time perhaps until what was held back about him bubbles up from the swamp where it had been safely kept
but you're not a man you're a chicken boo
twice times?
Kistiakowsky based his designs for the explosive lenses off of Bruno Rossi’s successful experiments with controlled symmetrical waves (Kunetka, p. 234). Standard rectangular blocks of explosive material were cut into the shape of a five- or six-sided pyramid with its tip cut off. In his interview, Kistiakowsky explained that “all of these lenses surrounded the tamper, and the tamper mainly served as a reflector for neutrons so that they go back.”
The tamper was a layer that surrounded the core of plutonium. Besides reflecting neutrons, Kistiakowsky added that the tamper helped “to smooth the shockwave that was produced by the detonation wave.” British physicist James Tuck, who was a member of the British Mission to Los Alamos, described the sphere of lenses around the core as resembling a soccer ball.
Best 3 out of 5
Goldman Sachs Asks 'Is Curing Patients A Sustainable Business Model?'
https://www.cbsnews.com/newyork/news/goldman-sachs-curing-patients-health-industry-report/
In an April 10 financial report titled "The Genome Revolution," company analysts allegedly posed the question "is curing patients a sustainable business model?" The report broke down the pros and cons of new gene therapy treatments being worked on by biotech companies. Turning the search for medical remedies into a numbers game, analyst Salveen Richter called potential "one shot cures" a bad business decision that will hurt a company's bottom line.
"While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," Richter said, via Yahoo Finance.
Goldman researchers pointed to pharmaceutical company Gilead Sciences, which developed a treatment for hepatitis C, as an example of the financial impact treating diseases can have on profits. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients," the memo argued.
Gilead Sciences' 90 percent cure rate of hepatitis C will reportedly send its sales plunging from $12.5 billion in 2015 to less than $4 billion this year. The Goldman Sachs report allegedly suggests that biotech firms move to developing treatments for conditions with larger patient pools such as spinal muscular atrophy and hemophilia.
a penal suppressor?